Emergent BioSolutions - EBS Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View EBS analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 12-month target prices for Emergent BioSolutions' stock. Their EBS share price forecasts range from $25.00 to $77.00. On average, they expect the company's share price to reach $46.50 in the next year. This suggests a possible upside of 275.6% from the stock's current price.
View analysts price targets for EBS or view top-rated stocks among Wall Street analysts.

Emergent BioSolutions' stock was trading at $43.47 at the start of the year. Since then, EBS shares have decreased by 71.5% and is now trading at $12.38.
View the best growth stocks for 2022 here.

Emergent BioSolutions saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 2,570,000 shares, an increase of 19.0% from the October 31st total of 2,160,000 shares. Based on an average daily trading volume, of 749,300 shares, the days-to-cover ratio is currently 3.4 days. Approximately 6.3% of the company's shares are sold short.
View Emergent BioSolutions' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our EBS earnings forecast.

Emergent BioSolutions Inc. (NYSE:EBS) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of $2.35 by $2.71. The biopharmaceutical company earned $329 million during the quarter, compared to analyst estimates of $484.77 million. Emergent BioSolutions had a trailing twelve-month return on equity of 9.52% and a net margin of 3.54%. The firm's quarterly revenue was down 14.6% compared to the same quarter last year. During the same period last year, the business earned $2.19 earnings per share.

Emergent BioSolutions issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.05 billion-$1.10 billion, compared to the consensus revenue estimate of $1.20 billion.

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Emergent BioSolutions' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (16.83%), Vanguard Group Inc. (10.41%), State Street Corp (8.65%), Dimensional Fund Advisors LP (3.86%), Jacobs Levy Equity Management Inc. (1.94%) and Neuberger Berman Group LLC (1.38%). Insiders that own company stock include Adam Havey, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Richard S Lindahl, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends.

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EBS stock can currently be purchased for approximately $12.38.

Emergent BioSolutions (NYSE:EBS) has a market capitalization of $617.61 million and generates $1.79 billion in revenue each year. The biopharmaceutical company earns $230.90 million in net income (profit) each year or $0.78 on an earnings per share basis.

The company employs 2,416 workers across the globe.

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899.